News Releases
- Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD May 28, 2020
- Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19 May 26, 2020
- Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19 May 25, 2020
- Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19 May 15, 2020
- Algernon Announces Closing of $6.8 Million Private Placement Offering, Including Exercise of the Over-Allotment Option May 13, 2020
- Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia May 6, 2020
- Algernon Amends Terms of Private Placement Offering of Special Warrants May 5, 2020
- Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants April 30, 2020
- Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial April 30, 2020
- Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial April 29, 2020